Nascent Biotech, Inc. (NBIO)

0.0998 0.0000 (0.00%) At close: 01:20PM EDT

Nascent Biotech, Inc.

631 US Hwy 1
Suite 407
North Palm Beach, FL 33408
United States
612 961 5656
https://www.nascentbiotech.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Sean Carrick	President, CEO, Secretary & Director	252k	N/A	1968
Mr. Lowell Holden	CFO, Chief Accounting Officer & Director	180k	N/A	1943
Dr. Mark C. Glassy Ph.D.	Founder	43k	N/A	1952
Dr. Navpaul Singh M.D.	Chief Medical Consultant	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. The company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. In addition, it develops CLNH5. The company has collaboration with Hypospray Pharma to develop an alternative delivery mechanism for patients who can benefit from Pritumumab. Nascent Biotech, Inc. is based in North Palm Beach, Florida.

Corporate governance

Nascent Biotech, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.